Growth inhibitor of human hepatic carcinoma HepG2 cells by evodiamine is associated with downregulation of PRAME
Authors:
- 29 July 2019
- journal article
- research article
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 392 (12) , 1551-1560
Abstract
Hepatocellular carcinoma (HCC) patients have low 5-year survival due to the delayed diagnosis, so it is necessary to develop an alternative treatment. Preferentially expressed antigen of melanoma (PRAME) has a high expression in HCC patients, and the effects of evodiamine on HCC are less characterized, although evodiamine has anti-tumor activities in several tumor types. To investigate the effects of evodiamine on PRAME expression, the in vitro PRAME expression in HepG2 cells after incubated with evodiamine was determined by RT-PCR and western blot. Cell viability, migration, invasion, and apoptosis of evodiamine-incubated HepG2 cells were evaluated by Cell Counting Kit-8, wound healing, transwell assay, and Annexin V-FITC/PI double-staining assay, respectively. To evaluate the mechanism of the regulation of evodiamine on the PRAME expression, chromatin immunoprecipitation coupled with quantitative PCR was employed. Xenograft model was used to evaluate the effects of evodiamine on tumor growth, survival rate, and the PRAME expression. The PRAME expression was inhibited in evodiamine-treated HepG2 cells in vitro and in vivo. The tumor metastasis and growth were inhibited resulting from evodiamine incubation. The evodiamine inhibited the PRAME expression through trimethylation of H3K27. In this study, evodiamine contributes to in vitro and in vivo tumor cell growth inhibition. To achieve this inhibition, the PRAME expression may be repressed through trimethylation resulting from epigenetic regulation of evodiamine.Keywords
Funding Information
- the Zhejiang Traditional Chinese Medicine Science and Technology Plan Project (2018ZA081)
This publication has 41 references indexed in Scilit:
- Identification of 67 Histone Marks and Histone Lysine Crotonylation as a New Type of Histone ModificationCell, 2011
- CBP-mediated acetylation of histone H3 lysine 27 antagonizesDrosophilaPolycomb silencingDevelopment, 2009
- Experimental mouse models for hepatocellular carcinoma researchInternational Journal of Experimental Pathology, 2009
- Evodiamine: A Novel Anti-Cancer Alkaloid from Evodia rutaecarpaMolecules, 2009
- PRAME expression and clinical outcome of breast cancerBritish Journal of Cancer, 2008
- High-Resolution Profiling of Histone Methylations in the Human GenomeCell, 2007
- Chromatin Modifications and Their FunctionCell, 2007
- The Actual Five-year Survival Rate of Hepatocellular Carcinoma Patients after Curative ResectionYonsei Medical Journal, 2006
- The language of covalent histone modificationsNature, 2000
- Characterization of an Antigen That Is Recognized on a Melanoma Showing Partial HLA Loss by CTL Expressing an NK Inhibitory ReceptorImmunity, 1997